The CGTLive™ Oncology specialty topic page highlights the latest clinical care news related to the development of cell therapies, gene therapies, and engineered and regenerative medicines for various cancers. It also houses video interviews with key opinion leaders in the field of oncology speaking to the related FDA actions, clinical guideline updates, and clinical trial findings in the field of gene and cell therapy for oncologic diseases.
April 25th 2025
Review top news and interview highlights from the week ending April 25, 2025.
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Go To PER in Chicago
May 30, 2025 - June 3, 2025
Register Now!
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes
View More
Selinexor Approved Under Accelerated Pathway to Treat DLBCL
June 24th 2020The FDA granted accelerated approval to selinexor (Xpovio, Karyopharm Therapeutics) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The oral treatment is to be used after at least 2 lines of systemic therapy.
FDA Approves Selinexor for Relapsed/Refractory DLBCL
June 22nd 2020The FDA has approved selinexor for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.
Axi-Cel Induces Durable Remissions in Relapsed CLL, B-Cell Lymphoma
June 18th 2020Patients with relapsed chronic lymphocytic leukemia and B-cell lymphoma who received the anti-CD19 CAR T-cell therapy FMC63-28Z experienced highly durable rates of remission, according to long-term data from a phase 1/2 study.
CAG Regimen Shows Strong Results as Salvage Therapy in T-ALL
June 13th 2020Patients with relapsed/refractory T-cell lymphoblastic leukemia face poor outcomes, and are generally treated by salvage therapy followed by allogeneic hematopoietic stem cell transplant. A new study suggests an optimal option for salvage therapy.
Universal Allogeneic CAR T-Cell Product Demonstrates Efficacy in a Cohort of Adult T-ALL
April 29th 2020The first-in-clinic universal CAR T-cell therapy TruUCAR GC027 induced promising early response rates and demonstrated a manageable safety profile with no evidence of neurotoxicity events or graft-versus-host disease in adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia.
CAR T-Cell Therapy During the COVID-19 Pandemic: A Closer Look at Real-World Data
April 16th 2020This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor T cells. Join us Tuesday, May 19, 2020 at 8 PM EST.
Dr Karl Kilgore Outlines Challenges of Collecting Real-World Data on CAR T-Cell Therapy
March 18th 2020Several challenges arise when using real-world data derived from claims to study the impacts of CAR T-cell therapy on Medicare patients, said Karl Kilgore, PhD, senior research analyst at Avalere Health.
Ixazomib Frontline Triplet Misses PFS Endpoint in Transplant-Ineligible Myeloma
March 10th 2020The triplet therapy of ixazomib, lenalidomide, and dexamethasone showed an improvement in progression-free survival, but it was not statistically significant, compared with lenalidomide/dexamethasone alone for patients with newly diagnosed multiple myeloma who were ineligible for stem cell transplant.
Dr Karl Kilgore Discusses Benefits of CAR T-Cell Therapy for Medicare Patients
February 27th 2020Medicare patients' health care utilization, including hospitalizations and emergency department visits, decreased after CAR T-cell therapy, said Karl Kilgore, PhD, senior research analyst at Avalere Health.
Samantha Jaglowski, MD, MPH, Discusses Implications of Tisagenlecleucel for Patients with DLBCL
December 16th 2019The associate professor at The Ohio State University Comprehensive Cancer Center discussed the implications of her analysis of the CAR T-cell therapy tisagenlecleucel for patients with diffuse large B-cell lymphoma at the ASH Annual Meeting & Exposition.